Login to Your Account



FDA Briefing Docs: Preclinical Cancer a Worry for Isis Drug

By Randy Osborne
Staff Writer

Wednesday, October 17, 2012
Unexpected news for investors cropped up in briefing documents posted online by the FDA about Isis Pharmaceuticals Inc.'s lead cholesterol-lowering, antisense candidate Kynamro (mipomersen), and shares of the company took a daylong dive Tuesday as hopes for a positive vote weakened.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription